Indirubin derivative acts as dual inhibitor targeting proteasome and autophagy for treating multiple myeloma

被引：0
|
作者：
Fang, Teng [1 ]
Sun, Hao [1 ]
Sun, Xiyue [2 ]
Zhang, Xiaoyu [2 ]
Gong, Lixin [1 ]
Yu, Zhen [1 ]
Liu, Lanting [1 ]
Qiu, Lugui [1 ]
Hao, Mu [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol,Haihe Lab Cell Ecosyst, Tianjin 300020, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-189
引用
收藏
页码：S139 / S140
页数：2
相关论文
共 50 条
  • [1] Indirubin-3'-monoxime acts as proteasome inhibitor: therapeutic application in multiple myeloma
    Yu, Zhen
    Wei, Xiaojing
    Liu, Lanting
    Sun, Hao
    Fang, Teng
    Wang, Lu
    Li, Ying
    Sui, Weiwei
    Wang, Keifei
    He, Yi
    Zhao, Yaozhong
    Huang, Wenyang
    An, Gang
    Meng, Fancui
    Huang, Changjiang
    Yu, Tengteng
    Anderson, Kenneth
    Cheng, Tao
    Qiu, Lugui
    Hao, Mu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S101 - S102
  • [2] Indirubin-3' -monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma
    Yu, Zhen
    Wei, Xiaojing
    Liu, Lanting
    Sun, Hao
    Fang, Teng
    Wang, Lu
    Li, Ying
    Sui, Weiwei
    Wang, Kefei
    He, Yi
    Zhao, Yaozhong
    Huang, Wenyang
    An, Gang
    Meng, Fancui
    Huang, Changjiang
    Yu, Tengteng
    Anderson, Kenneth C.
    Cheng, Tao
    Qiu, Lugui
    Hao, Mu
    EBIOMEDICINE, 2022, 78
  • [3] Indirubin-3′-monoxime acts as an alternative proteasome inhibitor and confers new regimens for the treatment of Multiple Myeloma
    Yu, Zhen
    Liu, Lanting
    Wang, Kefei
    Sun, Hao
    Liu, Xiaojing
    Wei, Weiwei
    Wang, Lu
    Li, Ying
    Zhao, Yaozhong
    He, Yi
    An, Gang
    Meng, Fancui
    Yi, Shuhua
    Zou, Dehui
    Huang, Changjiang
    Cheng, Tao
    Qiu, Lugui
    Hao, Mu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S87 - S87
  • [4] Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK
    Salimi, Azam
    Schroeder, Kema Marlen
    Schemionek-Reinders, Mirle
    Vieri, Margherita
    Maletzke, Saskia
    Gezer, Deniz
    Masouleh, Behzad Kharabi
    Appelmann, Iris
    BMC CANCER, 2022, 22 (01)
  • [5] Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK
    Azam Salimi
    Kema Marlen Schroeder
    Mirle Schemionek-Reinders
    Margherita Vieri
    Saskia Maletzke
    Deniz Gezer
    Behzad Kharabi Masouleh
    Iris Appelmann
    BMC Cancer, 22
  • [6] Targeting Redox Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma
    Dolloff, Nathan G.
    Reyes, Leticia
    Smith, Brittany
    Langenheim, John Fairbanks
    Manevich, Yefim
    BLOOD, 2015, 126 (23)
  • [7] Novel combination therapy for treating proteasome inhibitor-resistant multiple myeloma
    Kim, Byung-Gyu
    Choi, Sung Hee
    Huong Nguyen
    Liang, Fu-Sen
    Kim, Seong-Jin
    Letterio, John
    Huang, Alex
    CANCER RESEARCH, 2024, 84 (06)
  • [8] Targeting autophagy in multiple myeloma
    Zhuang Yun
    Jin Zhichao
    Yao Hao
    Ji Ou
    Yang Ran
    Dong Wen
    Shen Qun
    LEUKEMIA RESEARCH, 2017, 59 : 97 - 104
  • [9] An oral proteasome inhibitor for multiple myeloma
    Pratt, Guy
    LANCET ONCOLOGY, 2014, 15 (13): : 1417 - 1418
  • [10] Proteasome inhibitor for treatment of multiple myeloma
    Ahmad, K
    LANCET ONCOLOGY, 2005, 6 (08): : 546 - 546
12345